Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kura Oncology (NQ: KURA )

19.89 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 19.89
Bid (Size) 7.960 (2)
Ask (Size) 31.62 (1)
Prev. Close 19.89
Today's Range 19.89 - 19.89
52wk Range 7.410 - 24.17
Shares Outstanding 68,438,576
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
KURA Stock Earnings: Kura Oncology Beats EPS for Q2 2024
KURA stock results show that Kura Oncology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
7 ‘Death Cross’ Stocks That Could Be Contrarian Buys
Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position. 
Via InvestorPlace

Performance

YTD
+29.49%
+29.49%
1 Month
+4.52%
+4.52%
3 Month
-7.79%
-7.79%
6 Month
-9.51%
-9.51%
1 Year
+104.00%
+104.00%

More News

Read More
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Via FinancialNewsMedia
2 Incredible Growth Stocks to Buy Hand Over Fist
Via The Motley Fool
Kura Oncology Inc. (NASDAQ: KURA) is a Stock Spotlight on 3/6
Via Investor Brand Network
Kura Oncology: Q4 Earnings Insights
Via Benzinga
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
From FN Media Group LLC
Via GlobeNewswire
KURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024
Via InvestorPlace
Earnings Scheduled For February 27, 2024
Via Benzinga
Earnings Outlook For Kura Oncology
Via Benzinga
Kura Oncology Inc. (NASDAQ: KURA) Near the Top of Equities by Percentage Gain on 1/24
Via Investor Brand Network
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
Via Talk Markets
Kura Makes Good On Its $150 Million Infusion And Shoots Up Another 15%
Via Investor's Business Daily
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Cancer-Drug Developer Kura Oncology Stock Is Up
Via Benzinga
General Motors Posts Upbeat Earnings, Joins Corning, HCA Healthcare And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Edges Lower; US Composite PMI Rises In January
Via Benzinga
Topics Stocks
Exposures US Equities
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?
Via Benzinga
Textron Posts Upbeat Earnings, Joins ASML, Progressive And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Kura Oncology Rockets 39% Before Unveiling Cancer Drug Test Results — Here's Why
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Clinical Advancements In Kura Oncology's Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.